People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Civitas Therapeutics, Inc. | — | Biotechnology | Series C | $117.8M | $2.3B | 2014 |
| Inozyme Pharma, Inc. | — | Pharmaceuticals | Series C | $116.2M | $2.4B | 2017 |
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2011 |
| Plexium, Inc. | — | Biotechnology | Series C | $60.1M | $361.1M | 2025 |
| Altheos, Inc. | — | Other | Series B | $23.1M | $275.1M | 2011 |
| Land Medicine Inc. | — | Pharmaceuticals | Series B | $16.9M | $97.8M | 2024 |
Rob Hopfner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rob Hopfner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy Shannon | 2 | 9 |
| David Hirsch | 1 | 16 |
| Wende Hutton | 1 | 16 |
| LEON CHEN | 1 | 15 |
| Edward Mathers | 1 | 12 |
| Michael Martin | 1 | 11 |
| Michael Grey | 1 | 10 |
| Peter Bisgaard | 1 | 9 |
| James Healy | 1 | 8 |
| James I. Healy | 1 | 7 |
| Axel Bolte | 1 | 6 |
| Bijan Salehizadeh | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Jake Nunn | 1 | 5 |
| Martin Edwards | 1 | 5 |
| Mark Iwicki | 1 | 4 |
| Glen Sato | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Lota S Zoth | 1 | 4 |
| Jake R. Nunn | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.